Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PARP inhibitors
15 evidence topics · 14 sources
Olaparib monotherapy: FDA-approved indication after enzalutamide or abiraterone
Olaparib monotherapy: PROfound efficacy, cohort A
| Outcome | Olaparib (n=162) | Enzalutamide or abiraterone acetate (n=83) |
|---|---|---|
| Median rPFS, months (95% CI) | “7.4 (6.2, 9.3)” | “3.6 (1.9, 3.7)” |
| rPFS hazard ratio (95% CI) | “0.34 (0.25, 0.47)” | Not applicable |
| Median OS, months (95% CI) | “19.1 (17.4, 23.4)” | “14.7 (11.9, 18.8)” |
| OS hazard ratio (95% CI) | “0.69 (0.50, 0.97)” | Not applicable |
Olaparib monotherapy: PROfound primary publication
“We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Anemia and nausea were the main toxic effects in patients who received olaparib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Olaparib monotherapy: PROfound overall survival publication
“The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P = 0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5 months with control therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 86 of 131 patients (66%) in the control group crossed over to receive olaparib (56 of 83 patients [67%] in cohort A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rucaparib: FDA-approved indication after androgen receptor-directed therapy
Rucaparib: TRITON3 efficacy, BRCA-mutated subgroup
| Outcome | Rucaparib (N=201) | Androgen receptor pathway inhibitor or docetaxel (N=101) |
|---|---|---|
| Median rPFS, months (95% CI) | “11.2 (9.2-13.8)” | “6.4 (5.4-8.3)” |
| rPFS hazard ratio (95% CI) | “0.50 (0.36, 0.69)” | Not applicable |
| Median OS, months (95% CI) | “23.2 (19.1, 25.2)” | “21.2 (18.0, 23.1)” |
| OS hazard ratio (95% CI) | “0.91 (0.68, 1.20)” | Not applicable |
| Overall response rate, % (95% CI) | “45.1 (34.1, 56.5)” | “17.1 (7.2, 32.1)” |
Rucaparib: TRITON3 crossover and ATM subgroup
Rucaparib: TRITON3 comparisons with docetaxel and with a second inhibitor
“In the BRCA subgroup, the median duration of imaging-based progression-free survival was longer with rucaparib than with docetaxel (11.2 months vs. 8.3 months; hazard ratio, 0.53; 95% CI, 0.37 to 0.77)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the median duration was also longer with rucaparib than with abiraterone acetate or enzalutamide (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% CI, 0.25 to 0.58)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on PARP inhibitors in pretreated disease
First-line combination in inhibitor-naive disease: olaparib with abiraterone
| Outcome (BRCA-mutated subgroup, exploratory) | Olaparib plus abiraterone (N = 47) | Placebo plus abiraterone (N = 38) |
|---|---|---|
| Median rPFS, months (95% CI) | “NR (NR, NR)” | “8 (6, 15)” |
| rPFS hazard ratio (95% CI) | “0.24 (0.12, 0.45)” | Not applicable |
| Median OS, months (95% CI) | “NR (NR, NR)” | “23 (18, 34)” |
| OS hazard ratio (95% CI) | “0.30 (0.15, 0.59)” | Not applicable |
First-line combination in inhibitor-naive disease: PROpel publication
“We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-line combination: talazoparib with enzalutamide
| Outcome (TALAPRO-2, HRR gene-mutated) | Talazoparib with enzalutamide (N=200) | Placebo with enzalutamide (N=199) |
|---|---|---|
| Median rPFS by BICR, months (95% CI) | “NR (21.9, NR)” | “13.8 (11.0, 16.7)” |
| rPFS hazard ratio (95% CI) | “0.45 (0.33, 0.61)” | Not applicable |
| Median OS, months (95% CI) | “45.1 (35.4, NR)” | “31.1 (27.3, 35.4)” |
| OS hazard ratio (95% CI) | “0.62 (0.48, 0.81)” | Not applicable |
First-line combination: TALAPRO-2 all-comers publication
“TALAPRO-2 is a randomised, double-blind, phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy in men (age ≥18 years [≥20 years in Japan]) with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the planned primary analysis, median rPFS was not reached (95% CI 27·5 months-not reached) for talazoparib plus enzalutamide and 21·9 months (16·6-25·1) for placebo plus enzalutamide (hazard ratio 0·63; 95% CI 0·51-0·78; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
First-line combination: niraparib with abiraterone acetate
| Outcome (MAGNITUDE, BRCA-mutated subgroup) | Niraparib with abiraterone acetate (N=113) | Placebo with abiraterone acetate (N=112) |
|---|---|---|
| Median rPFS, months (95% CI) | “16.6 (13.9, NE)” | “10.9 (8.3, 13.8)” |
| rPFS hazard ratio (95% CI) | “0.53 (0.36, 0.79)” | Not applicable |